Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced its “first-in-patient” in a Phase 1/2 clinical trial for… Read More »Opus Genetics Inc., has announced the “first-in-patient” in a Phase 1/2 clinical trial for “OPGx-001” for the treatment of LCA5 retinal disease.
Clinical researchers from the US, Canada and the Netherlands, have reported a study to recommend clinical trial designs and outcomes for XLRP (X-linked retinitis pigmentosa). … Read More »Clinical trial development and trial outcome measures have published recommendations for XLRP studies.
Researchers at the Centre for Medical Image Computing, University College London, London, UK and the Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust,… Read More »Researchers at UCL and Moorfields Eye Hospital have reported an AI “foundation model” for ophthalmology, published in the journal Nature.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the October 3rd, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »October 3rd, 2023 “EURETINA-Brief”© Issue No. 279
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key results from a Phase 2 clinical trial, “STARLIGHT”, at the American Society of… Read More »Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy.
Principal investigators Dr. Aaron Nagiel, MD, PhD, at Children’s Hospital of Los Angeles, and Dr. Lesley Everett, MD, PhD, MPhil, at the Oregon Health Sciences… Read More »Clinical researchers on X-linked retinoschisis (XLRS) reports the dosing of a first patient in a phase 1 / 2 study.
Researchers at the Department of Ophthalmology, University of California, Irvine and the Structural Biology Research Centre, Vrije Universiteit Brussels, Belgium, have reported the use of… Read More »US & Belgium research team discover a novel “nanobody” (a “mini-antibody”) potentially applicable to retinitis pigmentosa (RP) treatment.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 14th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »September 14th, 2023 “EURETINA-Brief”© Issue No. 278
Beacon Therapeutics, based in London and Oxford, UK, have recently announced an investment of £96 million (€112 million) to fund the acquisition of AGTC (Applied… Read More »Beacon Therapeutics have announced the acquisition of AGTC (NASDAQ: AGTC), supported by Syncona Ltd and Oxford Science Enterprises.
FDA approval of visual gains and safety of aflibercept (8mg) were announced on August 18th, indicated for the treatment of patients with wet age-related macular… Read More »Aflibercept (8mg) has been approved for wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR).